Analysts Set Envista Holdings Corporation (NYSE:NVST) Price Target at $28.83

by · The Cerbat Gem

Envista Holdings Corporation (NYSE:NVST – Get Free Report) has been given an average recommendation of “Hold” by the fifteen analysts that are presently covering the stock, Marketbeat.com reports. Nine analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $28.8333.

NVST has been the subject of a number of analyst reports. Leerink Partners set a $35.00 price objective on shares of Envista and gave the company an “outperform” rating in a research report on Friday, February 6th. Wall Street Zen lowered shares of Envista from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Weiss Ratings lowered shares of Envista from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 11th. Morgan Stanley raised their price objective on shares of Envista from $19.00 to $21.00 and gave the company an “equal weight” rating in a research report on Friday, April 24th. Finally, Citigroup initiated coverage on shares of Envista in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $29.00 price objective for the company.

View Our Latest Stock Analysis on Envista

Envista Price Performance

NVST opened at $23.73 on Thursday. The company has a market capitalization of $3.86 billion, a price-to-earnings ratio of 57.89, a PEG ratio of 1.44 and a beta of 0.92. The company has a quick ratio of 2.06, a current ratio of 2.44 and a debt-to-equity ratio of 0.47. The firm has a 50-day moving average price of $25.68 and a 200-day moving average price of $24.29. Envista has a twelve month low of $16.41 and a twelve month high of $30.42.

Envista (NYSE:NVST – Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.05. The firm had revenue of $705.50 million during the quarter, compared to the consensus estimate of $680.04 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. The company’s revenue was up 14.4% on a year-over-year basis. During the same quarter last year, the company earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities analysts expect that Envista will post 1.43 EPS for the current year.

Institutional Investors Weigh In On Envista

Hedge funds have recently bought and sold shares of the stock. Tudor Investment Corp ET AL purchased a new position in Envista during the 3rd quarter valued at $1,664,000. ARGA Investment Management LP purchased a new stake in shares of Envista in the 3rd quarter worth about $950,000. First Eagle Investment Management LLC purchased a new stake in shares of Envista in the 3rd quarter worth about $4,329,000. Massachusetts Financial Services Co. MA grew its position in shares of Envista by 22.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,905,149 shares of the company’s stock worth $59,178,000 after buying an additional 523,949 shares during the period. Finally, Jupiter Asset Management Ltd. grew its position in Envista by 24.6% during the 3rd quarter. Jupiter Asset Management Ltd. now owns 1,349,042 shares of the company’s stock valued at $27,480,000 after purchasing an additional 266,671 shares during the last quarter.

Envista Company Profile

(Get Free Report)

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.

Featured Stories